Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial

Por Tebbutt, N C, Parry, M M, Zannino, D, Strickland, A H, Van Hazel, G A, Pavlakis, N, Ganju, V, Mellor, D, Dobrovic, A, Gebski, V J
Publicado em 2013

Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer

Por Weickhardt, A J, Williams, D S, Lee, C K, Chionh, F, Simes, J, Murone, C, Wilson, K, Parry, M M, Asadi, K, Scott, A M, Punt, C J A, Nagtegaal, I D, Price, T J, Mariadason, J M, Tebbutt, N C
Publicado no Br J Cancer (2015)